Notice of Results

Oxford Biomedica PLC
05 September 2005


FOR IMMEDIATE RELEASE                                          5 SEPTEMBER 2005

                              OXFORD BIOMEDICA PLC

                           NOTICE OF INTERIM RESULTS
                     FOR THE SIX MONTHS ENDED 30 JUNE 2004

Oxford, UK: 5 September 2005 - Oxford BioMedica (LSE:OXB.L), the leading gene
therapy company, announces that it will be releasing its interim results for the
six months ended 30 June 2005 on Tuesday, 20 September 2005.

Meetings:

An analyst briefing will be held at 10:00 am on the day. The venue for the
meeting will be Buchanan Communications, 107 Cheapside, London EC2V 6DN.

Web cast:

Simultaneously to the analyst briefing, there will be a live audio web cast of
the results presentation.

To connect to the web cast facility, please go to the Company's website:
http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:50 am) before the
start of the briefing. This will also be available for replay shortly after the
presentation.

                                     -Ends-

For further information, please contact:
Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive               Tel: [phone]
City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson
Buchanan Communications                                Tel: [phone]
Scientific/Trade Press Enquiries:
Sue Charles/ Katja Stout/ Ashley Lilly
Northbank Communications                               Tel: [phone]


Notes to editors

1. Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes an immunotherapy and a gene therapy in multiple Phase II trials, and a
preclinical targeted antibody therapy in collaboration with Wyeth. In
neurotherapy, the Company's lead product is a gene therapy for Parkinson's
disease, which is expected to enter clinical trials in 2006, and four further
preclinical candidates. The Company is underpinned by over 80 patent families,
which represent one of the broadest patent estates in the field.

The Company has a staff of approximately 65 split between its main facilities in
Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Viragen,
MolMed and Kiadis; and has licensed technology to a number of companies
including Merck & Co, Biogen Idec and Pfizer.
Further information is available at http://www.oxfordbiomedica.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange